老虎证券

BRIEF-EMA's CHMP Recommends Against Sanofi's Rezurock

Reuters
10/17
BRIEF-EMA's CHMP Recommends Against <a href="https://laohu8.com/S/GCVRZ">Sanofi</a>'s Rezurock

Oct 17 (Reuters) - EMA's CHMP:

  • EMA'S CHMP: ADOPTED POSITIVE OPINION FOR WAYRILZ FOR TREATMENT OF IMMUNE THROMBOCYTOPENIA IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS

  • EMA'S CHMP: RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR BRINSUPRI

  • EMA'S CHMP: RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR REZUROCK FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE

  • EMA'S CHMP: WITHDRAWS INITIAL MARKETING APPLICATION FOR HYDROCORTISONE AGUETTANT

  • EMA'S CHMP: ADOPTED NEW SUBCUTANEOUS ROUTE OF ADMINISTRATION FOR SAPHNELO, AN ADD-ON TREATMENT IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

  • EMA'S CHMP: CONFIRMED ITS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE

  • EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR BREYANZI

  • EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR TREMFYA

  • EMA'S CHMP: CONFIRMS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE AS NEW ACTIVE SUBSTANCE

  • EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR PAXLOVID

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10